No abstract available.
Prostatic Hyperplasia*

No abstract available.
Prostatic Hyperplasia

No abstract available.
Prostatic Hyperplasia*

No abstract available.
Hyperplasia* ; Prostate* ; Prostatic Hyperplasia ; Prostatic Neoplasms

The study was made on 42 benign prostatic hyperplasia patients. The results showed that after one month therapy by traditional medication, symptoms scoring index IPSS reduced from 21.0 to 11.71 (p<0.05). The flow of urinary increased from 4.56ml/s to 8.98ml/s (p<0.05). Residual urine volume reduced from 16.52ml to 8.35ml (p<0.05). The therapeutic outcomes by the extract of "Than khi hoan gia giam" were classified as follows: Good in 23 cases (54.8%), Moderate in 15 cases (35.7%), Poor in 4 cases (9.5%).
Prostatic Hyperplasia ; Therapeutics ; Prostatic Hyperplasia ; Medicine, Traditional

No abstract available.
Laser Coagulation* ; Prostatic Hyperplasia*

No abstract available.
Apoptosis* ; Prostate* ; Prostatic Hyperplasia*

The clinical effect of prazosin, an alpha-1-receptor blocking agent, was studied in 31 patients with benign prostatic hypertrophy. The daily dose of 1.5-6 mg of prazosin was given for 2 weeks to 3 months. The efficacy was assessed by using uroflowmetry calculated from maximum flow rate, average flow rate and residual urine volume. The result revealed significant improvement of day time frequency, night time frequency (p<0.05) and maximum and average flow rate (p<0.05). It was suspected that prazosin was the valuable alpha-1-receptor blocker for benign prostatic hypertrophy and worth while to initiate medical treatment before undergoing any surgical intervention or when surgery is contraindicated.
Humans ; Prazosin* ; Prostatic Hyperplasia*

No abstract available.
Prostatectomy* ; Prostatic Hyperplasia

The literature has suggested that alpha-receptor blockade may have therapeutic value in treating the symptoms of patients with benign prostatic hypertrophy. Terazosin is an alpha-1 adrenergic blocking agent approved by the FDA for the treatment of benign prostatic hypertrophy. We treated 30 patients with symptomatic benign prostatic hypertrophy in double- blind fashion using terazosin and placebo. In placebo group, mean total symptom score was decreased from 9.8 to 7.7 (p <0.0001), but was statistically significant in only obstructive symptom score. Changes in maximal and mean urinary flow rates were from 9.8 to 10.3 and from 4.9 to 5.3, respectively, but there was no statistical significance (p>0.05). In terazosin group, the symptom score changes in obstructive and irritative were from 6.1 to 3.3 and from 4.5 to 5.9 (p <0.0001), respectively, and changes in maximal and mean urinary flow rates were from symptoms 8.7 to 10.2 and from 4.2 to 5.9, respectively (p<0.0001). There were significant improvements in all parameters in terazosin group when compared with placebo group (p<0.05). It was concluded that terazosin is beneficial for treatment of obstructive symptoms in patients with benign prostatic hypertrophy.
Humans ; Prostatic Hyperplasia*